Salvage allogeneic hematopoietic stem cell transplantation under venetoclax bridging myeloablative preconditioning regimen for an acute myeloid leukemia patient with primary induction therapy failure
10.3760/cma.j.cn115356-20201103-00260
- VernacularTitle:应用维奈克拉桥接清髓性预处理方案的挽救性异基因造血干细胞移植治疗原发诱导治疗失败的急性髓系白血病一例
- Author:
Haixia ZHOU
1
;
Shengli XUE
;
Mingzhu XU
;
Liyun CHEN
;
Chongsheng QIAN
;
Yin LIU
;
Aining SUN
;
Depei WU
Author Information
1. 苏州大学附属第一医院血液科 江苏省血液研究所 卫生部血栓与止血重点实验室 国家血液系统疾病临床医学研究中心，江苏 苏州 215006
- Keywords:
Leukemia, myeloid, acute;
Venetoclax;
Induction chemotherapy;
Salvage therapy;
Hematopoietic stem cell transplantation
- From:
Journal of Leukemia & Lymphoma
2021;30(9):534-537
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the application of venetoclax in transplantation of patients with refractory acute myeloid leukemia (AML).Methods:The diagnosis and treatment process of a patient with refractory AML who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) under venetoclax and hypomethylating agents bridging myeloablative preconditioning regimen after induction therapy failure in the First Affiliated Hospital of Soochow University in March 2020 were retrospectively analyzed.Results:The patient was a 28-year-old female who was diagnosed with refractory AML. The patient was initially given induction chemotherapy with IA (idarubicin+cytarabine) (3+7) regimen, but the disease did not relieve, then the induction chemotherapy with CLAG (cladribine+cytarabine+granulocyte colony stimulating factor) regimen was given, but the disease still did not relieve. After chemotherapy with venetoclax and hypomethylating agents bridging myeloablative preconditioning regimen, salvage haploid allo-HSCT was performed. Re-examination of bone marrow showed remission, and implantation was successful. The patient was followed up for 100 days and had sustained remission, and no transplantation complications occurred.Conclusion:For refractory AML patients who have failed primary induction therapy, the use of venetoclax and hypomethylating agents bridging myeloablative preconditioning regimen can be used as a preferred solution for salvage allo-HSCT.
